---
title: "Outlook Therapeutics, Inc. (OTLK.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/OTLK.US/overview.md"
symbol: "OTLK.US"
name: "Outlook Therapeutics, Inc."
parent: "https://longbridge.com/zh-HK/quote/OTLK.US.md"
datetime: "2026-04-05T16:46:44.235Z"
locales:
  - [en](https://longbridge.com/en/quote/OTLK.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OTLK.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OTLK.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/OTLK.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/OTLK.US/overview.md)


# Outlook Therapeutics, Inc. (OTLK.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Biotechnology |
| 交易所 | US Market |
| 地址 | 111 S. Wood Avenue, Unit #100, Iselin, New Jersey, United States |
| 官網 | [outlooktherapeutics.com](https://outlooktherapeutics.com) |

## 公司簡介

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Robert Charles Jahr | President, CEO & Director |
| Faisal G. Sukhthian | Independent Chairman of the Board |
| Lawrence A. Kenyon | EVP, CFO, Treasurer, Secretary & Director |
| Joel Prieve | Senior Vice President of Licensing and M&A |
| Surendra Sharma | Senior Vice President of Medical Affairs |
| Jennifer M. Kissner | Senior Vice President of Clinical Development & Regulatory Affairs |
| Kurt J. Hilzinger | Independent Director |
| Ralph H. Thurman | Lead Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| GMS Ventures & Investments | 12.95% | 2025-05-27 |
| Schonfeld Strategic Advisors LLC | 2.33% | 2025-12-31 |
| Syntone Technologies Group Co. Ltd. | 1.63% | 2025-01-15 |
| Armistice Capital LLC | 1.53% | 2025-03-28 |
| The Vanguard Group, Inc. | 1.40% | 2025-12-31 |
| BlackRock, Inc. | 0.39% | 2025-12-31 |
| Gilpin Wealth Management LLC | 0.34% | 2025-12-31 |
| Geode Capital Management, LLC | 0.30% | 2025-12-31 |
| Marshall Wace LLP | 0.29% | 2025-12-31 |
| UBS Asset Management AG | 0.20% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| Biotechnology | 1413535 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Outlook Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| United States | 1413535 | 100% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**